Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 44Lenalidomide 29Bortezomib 23daratumumab 22pomalidomide 19Cyclophosphamide 15carfilzomib 14Specimen Handling 14Biopsy 14Calcium Dobesilate 12Magnetic Resonance Spectroscopy 10talquetamab 9isatuximab 9Melphalan 8iberdomide 7fludarabine 7belantamab mafodotin 6dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5X-Rays 5tocilizumab 4selinexor 4fludarabine phosphate 4elotuzumab 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Fumigant 93 × 30 days × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡